Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BSN medical Investment Pays Off For EQT In €2.7bn Deal

Executive Summary

BSN medical is changing owners for the third time in a decade, with a multi-billion-euro deal that will see the wound-care and orthopedics specialist enter the folds of SCA, a Swedish group that sells consumer health-care products, among other things.

You may also be interested in...



Device/Diagnostics Quarterly Deal Statistics, Q4 2016

Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.

BSN Chases Bigger Slice Of American Pie With Third Vascular Care Acquisition

BSN medical has completed a hat trick of acquisitions with its third lymphedema therapy-related purchase this year. The addition of Oakdale, Pennsylvania-based Wright Therapy Products, Inc. will further expand the US presence of BSN, which is headquartered in Hamburg, Germany, as well as add a new technology platform to its vascular care offering.

Private equity firm EQT wins €1.8bn bid for BSN

Confirming several weeks of speculation, German wound care specialist BSN Medical has a new owner – Swedish private equity firm EQT Partners. The deal has an enterprise value of €1.8bn ($2.25bn).

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104225

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel